Rare gene knockouts in adult humans
The total loss of protein-coding genes, even those with the potential to confer genetic diseases, can be tolerated.
www.science.orgHere’s a quick update on the latest publicly reported developments around gene knockout as of now.
-
What “gene knockout” means in modern research: Gene knockout refers to precisely disabling (inactivating) a specific gene to study its function or to validate a therapeutic target. In humans, researchers also study natural “knockouts”—people who naturally lack a working copy of a gene—to infer potential drug targets and tolerability. This concept remains central to translating genetic insights into medicines.[3][4][5]
-
Recent directions and notable themes:
- Natural human knockouts are being used to identify drugs with favorable safety profiles by observing individuals who lack certain genes but are otherwise healthy, guiding target selection and risk assessment for new therapies.[5][3]
- CRISPR-based knockout technologies continue to drive mechanistic studies in cells and animal models, enabling researchers to validate targets and explore downstream effects quickly.[2]
- Large-scale projects and consortia continue to catalog gene functions through knockout models, with findings feeding drug discovery pipelines and precision medicine approaches.[4][5]
-
Practical takeaways for researchers and readers:
- Gene knockout studies can reveal both therapeutic opportunities and potential side effects, underscoring the need for comprehensive phenotypic profiling when targeting a gene.[3]
- The existence of natural human knockouts supports the idea that some genes can be inhibited safely, while others may cause significant adverse effects, guiding clinical development decisions.[5][3]
- Public resources and discussions from major institutions emphasize using knockout data to prioritize targets with strong biological rationale and favorable safety margins.[10][5]
Illustrative example:
- A real-world example cited in industry discussions is the knockout of ketohexokinase (KHK) in humans, where individuals lacking the enzyme generally show no overt health issues, informing strategies to target KHK for metabolic diseases.[3]
If you’d like, I can narrow this to specific recent papers, ongoing clinical trials, or summarize how a particular gene knockout example informs drug development with citations. I can also pull more focused, location-relevant news (e.g., studies from Texas-area research centers) if you specify a gene or disease area.